Literature DB >> 9771402

A simple clinical colitis activity index.

R S Walmsley1, R C Ayres, R E Pounder, R N Allan.   

Abstract

BACKGROUND: The appropriate medical treatment of patients with ulcerative colitis is determined largely by the severity of symptoms. Hospital assessment of the severity of disease activity includes investigation of laboratory indices and sigmoidoscopic assessment of mucosal inflammation. AIMS: To develop a simplified clinical colitis activity index to aid in the initial evaluation of exacerbations of colitis.
METHODS: The information for development of the simple index was initially evaluated in 63 assessments of disease activity in patients with ulcerative colitis where disease activity was evaluated using the Powell-Tuck Index (which includes symptoms, physical signs, and sigmoidoscopic appearance). The new index was then further evaluated in 113 assessments in a different group of patients, by comparison with a complex index utilising clinical and laboratory data, as well as five haematological and biochemical markers of disease severity.
RESULTS: The newly devised Simple Clinical Colitis Activity Index, consisting of scores for five clinical criteria, showed a highly significant correlation with the Powell-Tuck Index (r = 0.959, p < 0.0001) as well as the complex index (r = 0.924, p < 0.0001) and all laboratory markers (p = 0.0003 to p < 0.0001).
CONCLUSIONS: This new Simple Colitis Activity Index shows good correlation with existing more complex scoring systems and therefore could be useful in the initial assessment of patients with ulcerative colitis.

Entities:  

Mesh:

Year:  1998        PMID: 9771402      PMCID: PMC1727189          DOI: 10.1136/gut.43.1.29

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  A simple index for assessment of disease activity in patients with ulcerative colitis.

Authors:  I Rutegård; L Ahsgren; R Stenling; T Nilsson
Journal:  Hepatogastroenterology       Date:  1990-12

2.  An index of disease activity in patients with ulcerative colitis.

Authors:  M Seo; M Okada; T Yao; M Ueki; S Arima; M Okumura
Journal:  Am J Gastroenterol       Date:  1992-08       Impact factor: 10.864

3.  Quantification of disease activity in patients with ulcerative colitis.

Authors:  H Kambe; T Yoshida; Y Haraguchi; T Iwashita; A Sakamoto; K Tanaka
Journal:  J Clin Gastroenterol       Date:  1986-12       Impact factor: 3.062

4.  Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease.

Authors:  P Gomes; C du Boulay; C L Smith; G Holdstock
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

5.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

6.  Determining disease activity in inflammatory bowel disease.

Authors:  W T Cooke; P Prior
Journal:  J Clin Gastroenterol       Date:  1984-02       Impact factor: 3.062

7.  The incidence and prevalence of inflammatory bowel disease in North Tees Health District.

Authors:  H B Devlin; D Datta; A W Dellipiani
Journal:  World J Surg       Date:  1980       Impact factor: 3.352

8.  Symptoms and stool patterns in patients with ulcerative colitis.

Authors:  S S Rao; C D Holdsworth; N W Read
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

9.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

10.  Ulcerative colitis and Crohn's disease health status scales for research and clinical practice.

Authors:  D A Drossman; Z Li; J Leserman; D L Patrick
Journal:  J Clin Gastroenterol       Date:  1992-09       Impact factor: 3.062

View more
  349 in total

1.  Hyperhomocysteinemia in Greek patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Dilaveraki; I G Vlachonikolis; E Vardas; G Vrentzos; E Ganotakis; I A Mouzas; A Gravanis; D Emmanouel; E A Kouroumalis
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

2.  New keys to maintenance treatment in ulcerative colitis.

Authors:  Peter D R Higgins
Journal:  Dig Dis       Date:  2010-09-30       Impact factor: 2.404

3.  Quality of life in patients with inflammatory bowel disease: translation, validity, reliability and sensitivity to change of the Norwegian version of the short health scale (SHS).

Authors:  Lars-Petter Jelsness-Jørgensen; Tomm Bernklev; Bjørn Moum
Journal:  Qual Life Res       Date:  2011-12-07       Impact factor: 4.147

4.  Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-Efficacy.

Authors:  Zaid Bilgrami; Ameer Abutaleb; Kenechukwu Chudy-Onwugaje; Patricia Langenberg; Miguel Regueiro; David A Schwartz; J Kathleen Tracy; Leyla Ghazi; Seema A Patil; Sandra M Quezada; Katharine M Russman; Charlene C Quinn; Guruprasad Jambaulikar; Dawn B Beaulieu; Sara Horst; Raymond K Cross
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

5.  Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease.

Authors:  Geoffrey C Nguyen; Thomas A LaVeist; Mary L Harris; Lisa W Datta; Theodore M Bayless; Steven R Brant
Journal:  Inflamm Bowel Dis       Date:  2009-08       Impact factor: 5.325

6.  Patient preferences for surgical versus medical therapy for ulcerative colitis.

Authors:  Meenakshi Bewtra; Vikram Kilambi; Angelyn O Fairchild; Corey A Siegel; James D Lewis; F Reed Johnson
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

Review 7.  Ulcerative Colitis: Update on Medical Management.

Authors:  Heba N Iskandar; Tanvi Dhere; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2015-11

8.  Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis.

Authors:  Francesco Azzolini; Cristiano Pagnini; Lorenzo Camellini; Antonella Scarcelli; Alberto Merighi; Anna Maria Primerano; Angela Bertani; Aldo Antonioli; Federico Manenti; Gian Piero Rigo
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

9.  A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease.

Authors:  Feiby L Nassan; Brent A Coull; Niels E Skakkebaek; Michelle A Williams; Ramace Dadd; Lidia Mínguez-Alarcón; Stephen A Krawetz; Elizabeth J Hait; Joshua R Korzenik; Alan C Moss; Jennifer B Ford; Russ Hauser
Journal:  Environ Int       Date:  2016-08-26       Impact factor: 9.621

10.  Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Niki Malliaraki; Philippos D Dimoulios; Konstantinos Karmiris; Elias Castanas; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.